Filing Flows › Health Care › Sera Prognostics (SERA)
Sera Prognostics (SERA) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Sera Prognostics (SERA) Q3 2026 earnings results →
Q3 2026 Revenue up 162% year over year to $42K
Sera Prognostics made $42K in Q3 2026 (+162% Y/Y). Operating margin n/m, net loss $8.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $42K in Q3 2026, up 162% year over year and up 40% from the previous quarter.
Operating costs exceeded revenue by $8.9M, an operating margin of -21159.5%. Total costs fell 1% while revenue rose 162%. The fastest-growing cost line was Sales & marketing (+41%). The quarter ended with a net loss of $8.1M, narrower than the previous quarter's $9.1M loss.
Operating cash flow was −$7.3M. Non-cash charges added back $192K of depreciation and amortization and $1.3M of share-based compensation. Working capital and other items used $718K. Capital expenditures of $134K exceeded it, leaving free cash flow of −$7.4M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $42K | +162% | n/m | −$8.1M | −$7.3M |
| Q2 2026 | 10-Q | Aug 12, 2026 | $30K | +76% | n/m | −$9.1M | −$6.3M |
| Q1 2026 | 10-Q | May 6, 2026 | $14K | -63% | n/m | −$8.4M | −$8.8M |
| Q4 2025 | 10-K | Mar 18, 2026 | $10K | -58% | n/m | −$7.9M | −$6.1M |
| Q3 2025 | 10-Q | Nov 13, 2025 | $16K | -45% | n/m | −$7.8M | −$6.5M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $17K | -29% | n/m | −$8.0M | −$5.5M |
| Q1 2025 | 10-Q | May 7, 2025 | $38K | — | n/m | −$8.2M | −$7.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Sera Prognostics
Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera’s mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera’s precision medicine PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is headquartered in Salt Lake City, Utah.
In its own words, from its 8-K, filed Aug 12, 2026.
Sera Prognostics against its Services-Medical Laboratories peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +162% against the peers' median +25%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| SERA Sera Prognostics | Q3 2026 | $42K | +162% | n/m |
| LH Labcorp Holdings | Q3 2026 | $3.8B | +7% | 10.6% |
| DGX Quest Diagnostics | Q3 2026 | $3.1B | +10% | 15.5% |
| NTRA Natera | Q3 2026 | $794M | +34% | -8.6% |
| FTRE Fortrea Holdings | Q3 2026 | $692M | -1% | 2.2% |
| RDNT RadNet | Q2 2026 | $623M | +25% | 6.3% |
| GH Guardant Health | Q3 2026 | $361M | +36% | -36.8% |
| CAI Caris Life Sciences | Q3 2026 | $275M | +27% | 7.0% |
| LMRI Lumexa Imaging Holdings | Q2 2026 | $264M | +5% | 8.7% |
Source: Sera Prognostics 10-Q on SEC EDGAR · CIK 1534969 · Services-Medical Laboratories
13F: who owns SERA and who is buying
More on SERA
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results